DOI: https://doi.org/10.15587/2519-4852.2016.87466

Chronic toxicity of the adamantane-1-ammonium salt of 2-(5-(adamantane-1-yl)-4-phenyl-1,2,4-triazole-3-thio)acetic acid substance

Віра Миколаївна Одинцова, Андрій Володимирович Абрамов, Ігор Федорович Бєленічев

Abstract


Nowadays, only seven adamantane derivatives have passed clinical trials as remedies applied for treatment of acne vulgaris, Alzheimer's disease, type 2 diabetes, and as antiviral drugs. The other are on the development stage as potential therapeutic agents for the treatment of diseases caused by iron overload, malaria, tuberculosis, neurological and oncological diseases, and as antioxidant and anti-inflammatory agents.

The aim of our research was to study chronic toxicity of adamantane-1-ammonium salt of 2-(5-(adamantane-1-yl)-4-phenyl-1,2,4-triazole-3-thio)acetic acid to obtain information on the toxicity syndrome and the further research as a promising drug.

Methods. Chronic toxicity study of adamantane-1-ammonium salt of 2-(5-(adamantane-1-yl)-4-phenyl-1,2,4-triazole-3-thio)acetic acid substance was carried out in accordance to requirements concerning  preclinical study of new drugs. While selecting the doses of the studied substance, we were guided by the data of preclinical studies of specific activity and results of SD50 and LD50 determination.

The experimental animals were kept in a separate room and were randomly divided into groups of 7 animals. The animals had a standard diet, getting the additive throughout the experiment. The substance was administered in the form of aqueous suspension. The control group got purified water in the same volume. The animals didn’t receive any meal 16 hours before administration of the substance; they got the remedy and the placebo at the same time.

Results. During the chronic experiment, no deaths of the rats and evidence toxicity manifestations were observed. Any deviations of appearance parameters, behavior, eating and drinking, connected with 2-(5-(adamantane-1-yl)-4-phenyl-1,2,4-triazole-3-thio)acetic acid use, were not observed. Also, no significant changes or side effects, connected with the substance administration, were found.

Conclusion. Preclinical trials of adamantane-1-ammonium salt of 2-(5-(adamantane-1-yl)-4-phenyl-1,2,4-triazole-3-thio)acetic acid toxicity has shown, that it is well tolerated by the animals, does not show toxic action signs, and no deaths were observed.

The given substance by the toxic safety nature is promising for the further research as a potential drug

Keywords


chronic toxicity studies; preclinical trials; 1;2;4-triazole; adamantine; experiments in animals; remedies

References


Blanpied, T. A. (2005). Amantadine Inhibits NMDA Receptors by Accelerating Channel Closure during Channel Block. Journal of Neuroscience, 25 (13), 3312–3322. doi: 10.1523/jneurosci.4262-04.2005

Maugh, T. (1979). Panel urges wide use of antiviral drug. Science, 206 (4422), 1058–1060. doi: 10.1126/science.386515

Sonnberg, L. (2003). The Complete Pill Guide: Everything You Need to Know about Generic and Brand-Name Prescription Drugs. Barnes & Noble Publishing, 87.

Ebtehal Suliman Al Abdullah. (2007). Synthesis and biological testing of new 1-adamantyl derivatives. Riyadh, Saudi Arabia, 147.

Skolimowski, J. (2003). Synthesis and antioxidant activity evaluation of novel antiparkinsonian agents, aminoadamantane derivatives of nitroxyl free radical. Bioorganic & Medicinal Chemistry, 11 (16), 3529–3539. doi: 10.1016/s0968-0896(03)00299-2

Zakon Ukrai'ny «Pro likars'ki zasoby» (1996). Verhovna Rada Ukrai'ny, # 123/96-VR. Available at: http://zakon2.rada.gov.ua/laws/show/123/96-vr

Nakaz Ministerstva ohorony zdorov’ja Ukrai'ny «Pro zatverdzhennja Porjadku provedennja doklinichnogo vyvchennja likars'kyh zasobiv ta ekspertyzy materialiv doklinichnogo vyvchennja likars'kyh zasobiv» (2009). MOZ Ukrai'ny, # 944. Available at: http://zakon3.rada.gov.ua/laws/show/z0053-10

Pinto, L. H., Holsinger, L. J., Lamb, R. A. (1992). Influenza virus M2 protein has ion channel activity. Cell, 69 (3), 517–528. doi: 10.1016/0092-8674(92)90452-i

Al-Deeb, O., Al-Omar, M., El-Brollosy, N., Habib, E., Ibrahim, T., El-Emam, A. (2011). Synthesis, Antimicrobial, and Anti-inflammatory Activities of Novel 2-[3-(1-Adamantyl)-4-substituted-5-thioxo-1,2,4-triazolin-1-yl]acetic Acids, 2-[3-(1-Adamantyl)-4-substituted-5-thioxo-1,2,4-triazolin-1-yl]propionic Acids and Related Derivatives. Arzneimittelforschung, 56 (01), 40–47. doi: 10.1055/s-0031-1296699

Kadi, A. A., El-Brollosy, N. R., Al-Deeb, O. A., Habib, E. E., Ibrahim, T. M., El-Emam, A. A. (2007). Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles. European Journal of Medicinal Chemistry, 42 (2), 235–242. doi: 10.1016/j.ejmech.2006.10.003

Giacino, J. T., Whyte, J., Bagiella, E., Kalmar, K., Childs, N., Khademi, A. et. al. (2012). Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. New England Journal of Medicine, 366 (9), 819–826. doi: 10.1056/nejmoa1102609

Kumar, C., Kwong, H., Mah, S., Chia, T., Loh, W.-S., Quah, C. et. al. (2015). Synthesis and Crystallographic Insight into the Structural Aspects of Some Novel Adamantane-Based Ester Derivatives. Molecules, 20 (10), 18827–18846. doi: 10.3390/molecules201018827

Lepahin, V. K., Astahova, A. V., Ushkalova, E. A., Illarionova, T. S., Fitilev, S. B., Shkrebneva, I. I. (2008). Razrabotka metodov izuchenija i profilaktiki oslozhnenij farmakoterapii. Moscow: RUDN, 225.

Stefanov, O. V. (Ed.) (2001). Doklinichni doslidzhennja likars'kyh zasobiv. Kyiv: Vyd. dim "Avicena", 527.


GOST Style Citations


1. Blanpied, T. A. Amantadine Inhibits NMDA Receptors by Accelerating Channel Closure during Channel Block [Text] / T. A. Blanpied // Journal of Neuroscience. – 2005. – Vol. 25, Issue 13. – P. 3312–3322. doi: 10.1523/jneurosci.4262-04.2005 

2. Maugh, T. Panel urges wide use of antiviral drug [Text] / T. Maugh // Science. – 1979. – Vol. 206, Issue 4422. – P. 1058–1060. doi: 10.1126/science.386515 

3. Sonnberg, L. The Complete Pill Guide: Everything You Need to Know about Generic and Brand-Name Prescription Drugs [Text] / L. Sonnberg. – Barnes & Noble Publishing, 2003. – P. 87.

4. Ebtehal Suliman Al Abdullah. Synthesis and biological testing of new 1-adamantyl derivatives [Text]: Ph.D. degree in pharm. sciences / Ebtehal Suliman Al Abdullah. – Riyadh, Saudi Arabia, 2007. – 147 p.

5. Skolimowski, J. Synthesis and antioxidant activity evaluation of novel antiparkinsonian agents, aminoadamantane derivatives of nitroxyl free radical [Text] / J. Skolimowski // Bioorganic & Medicinal Chemistry. – 2003. – Vol. 11, Issue 16. – P. 3529–3539. doi: 10.1016/s0968-0896(03)00299-2 

6. Закон України «Про лікарські засоби» [Текст]. – Верховна Рада України, 1996. – № 123/96-ВР. – Режим доступу: http://zakon2.rada.gov.ua/laws/show/123/96-вр

7. Наказ Міністерства охорони здоров’я України «Про затвердження Порядку проведення доклінічного вивчення лікарських засобів та експертизи матеріалів доклінічного вивчення лікарських засобів» [Текст]. – МОЗ України, 2009. – № 944. – Режим доступу: http://zakon3.rada.gov.ua/laws/show/z0053-10

8. Pinto, L. H. Influenza virus M2 protein has ion channel activity [Text] / L. H. Pinto, L. J. Holsinger, R. A. Lamb // Cell. – 1992. – Vol. 69, Issue 3. – P. 517–528. doi: 10.1016/0092-8674(92)90452-i 

9. Al-Deeb, O. Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-[3-(1-adamantyl)-4-substituted-5-thioxo-1,2,4-triazolin-1-yl]acetic acids, 2-[3-(1-adamantyl)-4-substituted-5-thioxo-1,2,4-triazolin-1-yl]propionic acids and related derivatives [Text] / O. Al-Deeb, M. Al-Omar, N. El-Brollosy, E. Habib, T. Ibrahim, A. El-Emam // Arzneimittelforschung. – 2006. – Vol. 56, Issue 01. – P. 40–47. doi: 10.1055/s-0031-1296699 

10. Kadi, A. A. Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles [Text] / A. A. Kadi, N. R. El-Brollosy, O. A. Al-Deeb, E. E. Habib, T. M. Ibrahim, A. A. El-Emam // European Journal of Medicinal Chemistry. – 2007. – Vol. 42, Issue 2. – P. 235–242. doi: 10.1016/j.ejmech.2006.10.003 

11. Giacino, J. T. Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury [Text] / J. T. Giacino, J. Whyte, E. Bagiella, K. Kalmar, N. Childs, A. Khademi et. al. // New England Journal of Medicine. – 2012. – Vol. 366, Issue 9. – P. 819–826. doi: 10.1056/nejmoa1102609 

12. Kumar, C. Synthesis and Crystallographic Insight into the Structural Aspects of Some Novel Adamantane-Based Ester Derivatives [Text] / C. Kumar, H. Kwong, S. Mah, T. Chia, W.-S. Loh, C. Quah et. al. // Molecules. – 2015. – Vol. 20, Issue 10. – P. 18827–18846. doi: 10.3390/molecules201018827 

13. Лепахин, В. К. Разработка методов изучения и профилактики осложнений фармакотерапии [Текст]: уч. пос. / В. К. Лепахин, А. В. Астахова, Е. А. Ушкалова, Т. С. Илларионова, С. Б. Фитилев, И. И. Шкребнева. – М.: РУДН, 2008. – 225 с.

14. Доклінічні дослідження лікарських засобів [Текст]: метод. рек. / ред. О. В. Стефанов. – К.: Вид. дім "Авіцена", 2001. – 527 c.







Copyright (c) 2016

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2519-4852 (Online), ISSN 2519-4844 (Print)